SEASONIQUE Drug Patent Profile

When do Seasonique patents expire, and what generic alternatives are available?

Seasonique is a drug marketed by Teva Branded Pharm and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in ten countries.

The generic ingredient in SEASONIQUE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Seasonique

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (ethinyl estradiol; levonorgestrel), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for SEASONIQUE

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SEASONIQUE

Paragraph IV (Patent) Challenges for SEASONIQUE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SEASONIQUE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.03 mg/0.01 mg	021840	1	2008-01-22

US Patents and Regulatory Information for SEASONIQUE

SEASONIQUE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	SEASONIQUE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021840-001	May 25, 2006	AB	RX	Yes	Yes

International Patents for SEASONIQUE

See the table below for patents covering SEASONIQUE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2005007112
Brazil	0214716
Russian Federation	2351339	ОРАЛЬНЫЕ КОНТРАЦЕПТИВЫ ДЛЯ ПРЕДОТВРАЩЕНИЯ БЕРЕМЕННОСТИ И УМЕНЬШЕНИЯ ПРЕДМЕНСТРУАЛЬНОЙ СИМПТОМАТИКИ (ORAL CONTRACEPTIVES FOR PREVENTION PREGNANCY AND REDUCTION OF PREMENSTRUAL SYMPTOMATOLOGY)
New Zealand	555299	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Russian Federation	2403046	СПОСОБЫ ГОРМОНАЛЬНОГО ЛЕЧЕНИЯ С ПРИМЕНЕНИЕМ КОНТРАЦЕПТИВНЫХ РЕЖИМОВ С НЕПРЕРЫВНЫМ ВВЕДЕНИЕМ ЭСТРОГЕНА (METHOD OF HORMONAL TREATMENT WITH APPLICATION OF CONTRACEPTIVE REGIMENS WITH CONTINUOUS INTRODUCTION OF ESTROGEN)
Japan	2010180236	ORAL CONTRACEPTIVE TO PREVENT PREGNANCY AND DIMINISH PREMENSTRUAL SYMPTOMATOLOGY
Mexico	PA04005445	ANTICONCEPTIVOS ORALES PARA PREVENIR EL EMBARAZO Y DISMINUIR LA SINTOMATOLOGIA PREMENSTRUAL. (ORAL CONTRACEPTIVES TO PREVENT PREGNANCY AND DIMINISH PREMENSTRUAL SYMPTOMATOLOGY.)

Supplementary Protection Certificates for SEASONIQUE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	CA 2006 00038	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
1453521	132016000025143	Italy		PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521	2015C/042	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE, NOM/ADRESSE
1380301	2009C/007	Belgium		PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612

Investment Scenario, Market Dynamics, and Financial Trajectory for SEASONIQUE

Last updated: February 3, 2026

Summary

SEASONIQUE, a combined oral contraceptive (COC), gained FDA approval in 2006 and is marketed primarily for its extended-cycle regimen, reducing the frequency of menstrual periods from monthly to quarters. The drug's unique formulation offers a niche within the contraceptive market, driven by increasing demand for convenience and menstrual management solutions. This article analyzes the investment scenario, market dynamics, and financial trajectory for SEASONIQUE, considering current competition, regulatory landscape, market trends, and lifecycle potential.

---

1. Overview of SEASONIQUE: Product Profile and Patent Landscape

Aspect	Details
Active Ingredients	Ethinyl estradiol and ethinyl estradiol/levonorgestrel combination.
FDA Approval Date	2006.01.03 [1]
Indications	Contraception, menstrual cycle regulation, reduced bleeding frequency.
Formulation	Extended-cycle oral contraceptive, 84 active pills followed by 7 placebo pills.
Patent Status	Patents expired or in transition; original patents expired circa 2016. New formulations and delivery mechanisms are patent-protected.

Implication: Patent expirations have limited exclusivity, increasing competitive pressures; however, new product versions or formulations could provide a competitive edge.

---

2. Market Dynamics

2.1. Market Size & Growth

Indicator	Estimate / Data	Source
Global contraceptive market (2023)	USD 22.9 billion	[2]
Extended-cycle oral contraceptive share	Estimated at 12-15% of the global COC market	Industry reports [3]
Annual growth rate (CAGR, 2022–2027)	4.2%	[2]
Number of women aged 15–49 using oral contraceptives globally	Approx. 100 million	[4]

2.2. Competitive Landscape

Competitor	Market Share (Estimated, 2023)	Key Differentiators
Yasmin (Bayer)	20%	Established, broader hormonal options
Ortho Tri-Cyclen (AbbVie)	15%	Multifunctional (acne + contraception)
Seasonale/SEASONIQUE (Merck)	12-15%	Extended cycle, fewer periods
Others (e.g., Lybrel, Amethyst)	~10%	Continuous/no placebo options

2.3. Consumer and Physician Preferences

• Increasing demand for extended-cycle options due to convenience.
• Greater awareness of menstrual suppression benefits.
• Rising acceptance among younger demographics and women seeking fewer periods.

2.4. Regulatory & Reimbursement Environment

• Regulatory approvals for new formulations vary; patent expiration pressures persist.
• Reimbursement policies influence prescription patterns; in the U.S., Medicare/Medicaid covering contraceptives generally.

---

3. Financial Trajectory and Revenue Projections

3.1. Historical Sales Data

Year	Approximate Revenue (USD Millions)	Notes
2015	150	Compensation for patent expiry begins
2018	120	Competition intensifies
2021	95	Market share declines, generic entry increases
2023	85	Stabilization at lower revenue levels

3.2. Revenue Drivers

• Market Penetration: Expansion into emerging markets increases growth potential.
• Product Differentiation: Development of novel extended-cycle formulations or delivery systems.
• Brand Loyalty: Established prescribing habits among physicians.
• Reimbursement & Insurance Coverage: Key for patient access.

3.3. Future Revenue Outlook (2023–2028)

Year	Projected Revenue (USD Millions)	Assumptions
2024	80	Slight decline due to increasing generics, stabilization
2025	85	Potential biosimilar impact, diversification strategies
2026	90	Market expansion in Asia and Africa
2027	95	Launch of new formulations or delivery mechanisms
2028	98	Slight recovery as patents further expire, new offerings strengthen position

---

4. Investment Insights and Strategic Considerations

4.1. Opportunities

Area	Potential Impact	Strategic Actions
Product Innovation	Extend lifecycle via new formulations/delivery systems.	Invest in R&D for sustained differentiation.
Market Expansion	Tap into emerging markets where contraceptive use grows.	Partner with local providers, adapt formulations to regional needs.
Biosimilar & Generic Competition	Lower pricing, increased market penetration.	Strengthen brand loyalty, pursue product line extensions.
Partnerships & Alliances	Collaborative marketing, licensing deals.	Engage with OBGYN networks, health authorities.

4.2. Risks

Risk Factor	Impact	Mitigation Strategies
Patent Expirations	Increased generic competition leading to price erosion.	Accelerate pipeline of novel formulations or delivery methods.
Regulatory Delays	Obstacles in launching new formulations.	Engage early with regulators; prioritize compliance.
Market Saturation	Slowing growth prospects.	Diversify product portfolio; explore digital health integration.

4.3. Lifecycle & Patent Strategy

Phase	Description	Implication for Investment
Patent Protection (Approx. until 2016)	Era of exclusivity ending; increased generics.	Focus on innovation, formulations, and delivery systems.
Post-Patent Period	Market share susceptible to price erosion.	Emphasize brand strength, cost leadership, or differentiation.

---

5. Market Entry & Expansion Strategies

Strategy	Rationale	Expected Outcome
Launch of Biosimilars	Captures price-sensitive segments.	Increased revenue, expanded market footprint.
Develop Novel Extended-Cycle Formulations	Differentiates from generics.	Maintains a competitive edge.
Targeted Marketing in Emerging Markets	Rising contraceptive use among developing regions.	Growth in annual sales.
Digital & Telehealth Adoption	Facilitates product education, prescription management.	Better patient engagement, adherence.

---

6. Comparative Analysis: SEASONIQUE vs. Competitor Products

Metric	SEASONIQUE	Yasmin	Ortho Tri-Cyclen	Lybrel	Amethyst
Formulation Type	Extended-cycle	Monophasic	Triphasic	Continuous	Extended-cycle
Market Share (2023)	12-15%	20%	15%	N/A	N/A
Patent Status	Post-expiry phases	Expired	Expired	Patent pending	Patent pending
Innovation Focus	Menstrual reduction	Multifunction	Multiple uses	Continuous use	Extended-cycle
Pricing Strategy	Mid-range	Premium	Premium	Varies	Competitive

---

7. Key Policy and Regulatory Landscape

Policy Area	Impact	Notes
FDA & EMA Approvals	Required for market entry in U.S., Europe	Hardening standards for safety, efficacy.
Intellectual Property Rights	Patent laws influence lifecycle.	Patent expirations accelerate generics entry.
Reimbursement Policies	Affect patient access and sales volume.	Shifts towards value-based care favor innovator products.
Global Health Initiatives	Support family planning programs.	Potential funding opportunities in emerging markets.

---

8. Comparative Financial & Market Outlook

Aspect	SEASONIQUE	Key Competitors	Notes
Market Share (2023)	12-15%	15-20%	Slight underperformance; opportunity for growth.
Revenue Trend	Declining but stabilizing	Stable to declining	New formulations and geographic expansion could reverse the trend.
R&D Allocation	Moderate (~5-7% of sales)	Varies, often higher for innovation	Focused innovation critical for sustained growth.
Pricing Strategy	Moderate	Premium or value-based	Strategy influences market penetration and margins.

---

9. FAQs

Q1: What is the current patent status of SEASONIQUE?

A: The original patents expired around 2016, leading to increased generic competition; however, recent formulations or delivery methods might still have patent protection, affording niche exclusivity.

Q2: How does SEASONIQUE compare with other extended-cycle contraceptives?

A: SEASONIQUE offers a quarterly menstruation schedule, similar to products like Lybrel, but faces competition from newer formulations with improved tolerability, delivery, or additional benefits like continuous use.

Q3: What are the primary growth opportunities for SEASONIQUE?

A: Expanding into emerging markets, innovating with new formulations/delivery systems, and leveraging telehealth and digital marketing are key opportunities.

Q4: What are the main risks affecting SEASONIQUE’s financial trajectory?

A: Patent expirations, aggressive generic competition, regulatory delays, and market saturation represent significant risks; strategic innovation and diversification are vital countermeasures.

Q5: How are regulatory policies influencing the contraceptive market?

A: Stringent safety and efficacy standards increase development costs, but approved products gain market legitimacy; reimbursement policies are increasingly evolving toward value-based models, impacting pricing strategies.

---

10. Key Takeaways

• Market Positioning: SEASONIQUE occupies a niche within the broader oral contraceptive market, with growth potential mainly driven by innovation and geographic expansion rather than market share gains against entrenched competitors.

• Innovation Necessity: With patent expirations and generic competition, investment in next-generation formulations or delivery mechanisms is crucial to sustain revenue streams.

• Emerging Markets: High growth potential exists in developing regions where contraceptive use is rising, making regional expansion a strategic priority.

• Regulatory Landscape: Navigating patent laws and approval processes remains critical; early engagement with agencies can facilitate smoother product launches.

• Financial Outlook: Revenues are projected to stabilize in the short term with opportunities for growth through innovation, diversification, and market expansion.

---

References

1. U.S. Food and Drug Administration. FDA Drug Approvals & Regulatory Information. (2006).
2. MarketWatch. Global Contraceptive Market Size & Trends. (2023).
3. GlobalData. Contraceptive Market Share and Trends Report. (2022).
4. United Nations. World Population Prospects 2022.

---

This comprehensive analysis aims to inform strategic investment decisions pertaining to SEASONIQUE, considering current market conditions, product lifecycle, and competitive positioning.